AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3902590
Drug: Prednisolone 0.5
RxNorm normalized name: prednisoLONE 0.5 % Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 0.5 mg/kg/day plus a normal diet
Trial: 3902590
Drug: Elemental diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elemental diet plus oral framycetin, colistin and nystatin
Trial: 30086036
Drug: Nonoperative Treatment
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonoperative Treatment (NOT)
Trial: 27656477
Drug: Intranasal Fluticasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal Fluticasone propionate aqueous nasal spray
Trial: 24553973
Drug: Oral Montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Montelukast
Trial: 17499304
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (sham treated group)
Trial: 27416912
Drug: Carfilzomib (10-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carfilzomib (10-min intravenous infusion; 20 mg/m2 on days 1 and 2 of cycle 1; 27 mg/m2 thereafter)
Trial: 27416912
Drug: Low-dose corticosteroids
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose corticosteroids (84 mg of dexamethasone or equivalent) with optional cyclophosphamide (1400 mg) for 28-day cycles
Trial: 27416912
Drug: Control (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (low-dose corticosteroids with optional cyclophosphamide)
Trial: 19241060
Drug: Chronic caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic caffeine administration (400 mg daily for > or =14 days)
Trial: 19241060
Drug: Acute caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute caffeine administration
Trial: 16838826
Drug: Taper-off program
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper-off program with group therapy
Trial: 16838826
Drug: Taper-off program
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taper-off program without group therapy
Trial: 16838826
Drug: Lower daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower daily benzodiazepine dosage at the start of tapering off
Trial: 16838826
Drug: Substantial dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Substantial dosage reduction by patients themselves just before tapering off
Trial: 12782534
Drug: Magnesium-aluminum-hydroxide-simethicone suspension
RxNorm normalized name: aluminum hydroxide / magnesium hydroxide / simethicone Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium-aluminum-hydroxide-simethicone suspension (MgAl)
Trial: 10697140
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of bismuth-based triple therapy (amoxicillin, metronidazole, bismuth subcitrate)
Trial: 10697140
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days of bismuth-based triple therapy (amoxicillin, metronidazole, bismuth subcitrate)
Trial: 9351030
Drug: Omeprazole 60
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole 60 mg twice daily plus Amoxicillin 750 mg three times daily for 10 days
Trial: 9351030
Drug: Ranitidine prophylaxis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine prophylaxis 150 mg at night for 2 years
Trial: 8224263
Drug: Clonidine (0.300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine (0.300 mg administered orally) once
Trial: 8224263
Drug: Growth hormone-releasing
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Growth hormone-releasing factor (GH-RF) (1 micrograms/kg IV) repeated twice
Trial: 8224263
Drug: Growth hormone-releasing
RxNorm normalized name: Growth hormone-releasing peptide 2
DrugBank: Pralmorelin (DB18252)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Growth hormone-releasing factor
Trial: 22207322
Drug: Iron infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron infusion during HD session
Trial: 22207322
Drug: Iron preparations
RxNorm normalized name: IRON PREPARATIONS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron preparations (iron gluconate, iron sucrose, iron dextran, ferric carboxymaltose)
Trial: 22207322
Drug: Culture of
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culture of mononuclear cells with iron preparations
Trial: 22207322
Drug: Generic formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Generic formulation of iron sucrose
Trial: 20598032
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol (400 microg/6 h)
Trial: 18076346
Drug: sapropterin 10
RxNorm normalized name: sapropterin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sapropterin 10 mg/kg/day (n = 41)
Trial: 9688015
Drug: High-dose albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose albuterol (two 5.0 mg doses administered during 40 minutes)
Trial: 9688015
Drug: Standard-dose albuterol
RxNorm normalized name: albuterol Metered Dose Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose albuterol (three 2.5 mg doses every 20 minutes)
Trial: 9688015
Drug: High-dose albuterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose albuterol
Trial: 2530123
Drug: High-dosage multivitamin
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dosage multivitamin and mineral supplements
Trial: 236108
Drug: Triazolam, 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam, 0.4 mg
Trial: 236108
Drug: Triazolam, 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triazolam, 0.8 mg
Trial: 236108
Drug: Flurazepam, 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurazepam, 15 mg
Trial: 236108
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active medications
Trial: 31981135
Drug: Counselor-administered home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counselor-administered home-based testing
Trial: 31981135
Drug: Access to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Access to antiretroviral therapy (ART)
Trial: 26525144
Drug: Multisystemic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multisystemic therapy for problem sexual behaviour (MST-PSB)
Trial: 21721591
Drug: Oxybutynin chloride
RxNorm normalized name: Oxybutynin Chloride
DrugBank: Oxybutynin (DB01062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oxybutynin chloride topical gel (OTG) 1 g containing oxybutynin chloride 10%, applied once daily to the abdomen, upper arm/shoulder, or thigh.
Trial: 21721591
Drug: Post-application showering
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-application showering (1-6 hours after dosing) and sunscreen application (30 minutes before or after OTG application).
Trial: 20053323
Drug: Alefacept treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alefacept treatment
Trial: 9580803
Drug: Continuous subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous subcutaneous apomorphine infusion
Trial: 9580803
Drug: Patch testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patch testing to apomorphine and its preservative
Trial: 3041822
Drug: Uniphyl tablets
RxNorm normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uniphyl tablets
Trial: 7332913
Drug: Theo-Dur tablets
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Theo-Dur tablets
Trial: 3041826
Drug: Uniphyl tablets
RxNorm normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uniphyl tablets and Theo-Dur tablets
Trial: 3041826
Drug: Uniphyl tablet
RxNorm normalized name: Uniphyl Tablets 400 MG Extended Release Oral Tablet
DrugBank: Theophylline (DB00277)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Uniphyl tablet phase
Trial: 23736378
Drug: FR-2 appliance
RxNorm normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FR-2 appliance treatment for 1.7 years
Trial: 23736378
Drug: FR-2 appliance
RxNorm normalized name: sodium polystyrene sulfonate
DrugBank: Tolevamer (DB01344)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FR-2 appliance treatment
Trial: 15082468
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg/day for 6 weeks
Trial: 15082468
Drug: Acetaminophen 1000
RxNorm normalized name: acetaminophen 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1000 mg four times a day for 6 weeks
Trial: 15082468
Drug: Patient preference
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient preference for Acetaminophen
Trial: 12149301
Drug: Gemcitabine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine plus 5-FU (600 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Trial: 12149301
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (1,000 mg/m(2)/wk) weekly for 3 weeks of every 4 weeks
Trial: 10460103
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 300 mg under fasting conditions
Trial: 10460103
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 300 mg with aluminum-magnesium antacid
Trial: 10460103
Drug: Isoniazid (INH)
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid (INH) 300 mg with a high-fat meal
Trial: 8570532
Drug: Cardizem tablets
DrugBank: Diltiazem (DB00343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cardizem tablets
Trial: 7130407
Drug: Group condition
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group condition (parent training plus group behavior therapy)
Trial: 7130407
Drug: Individual condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual condition (individual family behavior therapy)
Trial: 26044148
Drug: Vaginal progesterone
RxNorm normalized name: progesterone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal progesterone suppositories (400 mg daily starting at 20‐24 weeks of gestation)
Trial: 24531792
Drug: 2% ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketamine plus 4% amitriptyline (KA) cream
Trial: 23050461
Drug: LaSota vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LaSota vaccine (virus titers ranging from 10(2) to 10(8) EID50 in 10-fold increments)
Trial: 23050461
Drug: LaSota vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LaSota vaccine (adequate titer)
Trial: 19572933
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg pre-operatively (G2)
Trial: 19572933
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg post-operatively (G3)
Trial: 10094637
Drug: Lorazepam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (2 mg in 2 ml of normal saline)
Trial: 94637
Drug: Prazosin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (5 mg q.i.d.)
Trial: 94637
Drug: Methyldopa (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyldopa (500 mg q.i.d.)
Trial: 94637
Drug: Hydrochlorothiazide (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50 mg twice daily)
Trial: 31899371
Drug: Enhanced physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced physical activity monitor (Fitbit wearable activity monitor and mobile app with goal setting and physical activity prescription)
Trial: 28457189
Drug: Computerised cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerised cognitive remediation therapy (CCRT)
Trial: 23388155
Drug: MD-GAL (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-GAL (0.9 g MD/kg body mass (BM) per h and 0.3 g GAL/kg BM per h)
Trial: 23388155
Drug: MD-GAL-PRO+AA (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-GAL-PRO+AA (0.5 g MD/kg BM per h, 0.3 g GAL/kg BM per h, 0.4 g whey PRO hydrolysate plus l-leucine and l-phenylalanine/kg BM per h)
Trial: 21846036
Drug: Vacuum-therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacuum-therapy
Trial: 21846036
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no vacuum-therapy)
Trial: 10454977
Drug: Tirofiban plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirofiban plus heparin and aspirin
Trial: 10454977
Drug: Heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin and aspirin alone
Trial: 7531732
Drug: Cetirizine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetirizine (oral tablets) 10 mg twice daily
Trial: 399316
Drug: oestriol hemisuccinate
RxNorm normalized name: Oestriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oestriol hemisuccinate (12 mg/day)
Trial: 399316
Drug: oestriol hemisuccinate
RxNorm normalized name: Oestriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oestriol hemisuccinate (4-6 mg/day)
Trial: 9643277
Drug: Enalapril treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril treatment
Trial: 27443664
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pregabalin capsule (generic product)
Trial: 27443664
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg pregabalin capsule (reference brand Lyrica)
Trial: 23217470
Drug: Conventional gas‐torch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional gas‐torch brazing (G-TB)
Trial: 10212949
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at 750 mg/day or 1.5 g/day
Trial: 1816110
Drug: Aciclovir (1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aciclovir (1,500 mg/m2/d)
Trial: 1816110
Drug: Brivudin (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivudin (15 mg/kg/d)
Trial: 29849178
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil supplementation (0.33 to 4.50 g EPA+DHA/day) for 14 days
Trial: 29849178
Drug: Flaxseed oil
RxNorm normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed oil supplementation (5.90-6.60 g/d) for 14 days
Trial: 22040016
Drug: Parent‐Child Interaction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent‐Child Interaction Therapy Emotion Development (PCIT‐ED)
Trial: 20582464
Drug: Taxane resistance
RxNorm normalized name: acetaminophen / oxycodone hydrochloride Oral Capsule [Taxadone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taxane resistance (TET chemotherapy)
Trial: 18048574
Drug: Amlodipine (placebo,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (placebo, 5, or 10 mg) and Atorvastatin (placebo, 10, 20, 40, or 80 mg)
Trial: 18048574
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment of atorvastatin and amlodipine
Trial: 16221232
Drug: HB‐AS04 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB‐AS04 vaccine (Fendrix, GlaxoSmithKline Biologicals)
Trial: 16221232
Drug: Standard vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vaccine (Engerix, GlaxoSmithKline Biologicals)
Trial: 7757309
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg nimodipine t.i.d. for 7 days
Trial: 31987248
Drug: Korean red
RxNorm normalized name: Korean ginseng root
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean red ginseng (KRG) 3 g for 6 weeks
Trial: 29556335
Drug: Treatment with
RxNorm normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment with β‐aminoisobutyric acid in Dahl salt-sensitive rats
Trial: 25731657
Drug: Carbetocin (100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbetocin (100 μg IM)
Trial: 23418994
Drug: TABADO program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TABADO program (community-based smoking cessation program) including general information session, small-group sessions, individual counselling, and nicotine therapy if needed.
Trial: 16476840
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa at a dose of 10,000 U thrice weekly s.c.
Trial: 10607690
Drug: All-trans retinoic
RxNorm normalized name: all trans Retinoic acid
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All-trans retinoic acid (ATRA) during induction and maintenance therapy
Trial: 10607690
Drug: Chemotherapy without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chemotherapy without further ATRA
Trial: 10607690
Drug: No ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: No ATRA and no chemotherapy
Trial: 10607690
Drug: Maintenance therapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance therapy with ATRA
Trial: 9624473
Drug: Trimethoprim (TMP)
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trimethoprim (TMP) 10 mg/kg/day and Sulfamethoxazole (SMX) 50 mg/kg/day
Trial: 9624473
Drug: Pyrimethamine (P)
RxNorm normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrimethamine (P) 50 mg/day and Sulfadiazine (S) 60 mg/kg/day
Trial: 2966017
Drug: t‐PA 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA 25 mg and UK 0.5 million U (group I)
Trial: 2966017
Drug: t‐PA 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA 25 mg and UK 1.0 million U (group II)
Trial: 2966017
Drug: t‐PA 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA 1.0 mg/kg and UK 0.5 million U (group III)
Trial: 2966017
Drug: t‐PA 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA 1.0 mg/kg and UK 1.0 million U (group IV)
Trial: 2966017
Drug: t‐PA 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t‐PA 1.0 mg/kg and UK 2.0 million U (group V)
Trial: 27741182
Drug: 24-hour interval
RxNorm normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour interval administration of mifepristone and misoprostol
Trial: 27741182
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of mifepristone and misoprostol
Trial: 25133876
Drug: Inhaled budesonide
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled budesonide (ICS) for 8 weeks
Trial: 8573621
Drug: AdCFTR (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AdCFTR (2 x 10^5 to 2 x 10^8.5 plaque forming units) administered to the nasal epithelium of one nostril
Trial: 2596317
Drug: Acetazolamide 20
RxNorm normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetazolamide 20 mg/kg/day
Trial: 31504868
Drug: Increasing maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increasing maintenance methadone dose by 30%
Trial: 31504868
Drug: Adding oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding oxycodone
Trial: 31504868
Drug: Adding a
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adding a single dose of gabapentin
Trial: 31504868
Drug: Control condition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control condition (usual OAT dose)
Trial: 21756523
Drug: IV methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV methylprednisolone (MP) followed by oral MP (125 mg bolus, followed by 40 mg 6 hourly and then oral MP 0.6 mg/kg/day for 2 weeks)